Daniel E. C.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 2/3 Randomized Double-Blind Study of Liposomal Annamycin and Cytarabine vs. Placebo and Cytarabine in Refractory/Relapsed Acute Myeloid Leukemia
- Comparison of Seven-Day versus Continuous Venetoclax Exposure with Azacitidine in Treatment-Naïve Patients with Ineligible-for-Intensive Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 2 of 46 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on developing therapeutic strategies for patients with refractory and relapsed conditions.
- Advanced AML Treatment
- Second-line Therapy Development
- Combination Treatment Approaches
The investigator's work emphasizes innovative therapeutic combinations to enhance remission rates in challenging blood cancer cases.
Treatment Optimization
The researcher focuses on optimizing dosage regimens for novel therapeutic combinations in hematologic malignancies, particularly examining different dosing strategies for maximum clinical benefit.
- Dosage Optimization Studies
- Treatment Response Assessment
- Remission Induction Strategies
Their work involves evaluating treatment efficacy through complete remission rates in adult patients.
Clinical Innovation
The investigator specializes in developing combination therapy approaches for blood cancers, particularly focusing on integrating novel compounds with established treatments.
- Novel Drug Combinations
- Treatment Resistance
- Adult Leukemia Therapy
Their research encompasses therapeutic solutions for patients who have not responded to initial treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.